Literature DB >> 34556826

Integrin-based therapy in IBD.

Eleni Kotsiliti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34556826     DOI： 10.1038/s41575-021-00526-1

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  2 in total

1.  Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.

Authors:  Emily Becker; Mark Dedden; Christine Gall; Maximilian Wiendl; Arif Bülent Ekici; Anja Schulz-Kuhnt; Anna Schweda; Caroline Voskens; Ahmed Hegazy; Francesco Vitali; Raja Atreya; Tanja Martina Müller; Imke Atreya; Markus F Neurath; Sebastian Zundler
Journal:  Gut       Date:  2021-08-30       Impact factor: 31.793

2.  Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis.

Authors:  Christopher J Tyler; Mauricio Guzman; Luke R Lundborg; Shaila Yeasmin; Nadia Zgajnar; Paul Jedlicka; Giorgos Bamias; Jesús Rivera-Nieves
Journal:  Mucosal Immunol       Date:  2021-08-25       Impact factor: 7.313
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.